Skip to main content
SpringerLink
Log in

Tumeurs urologiques du sujet âgé

  • Chapter
Cancer du sujet âgé

Part of the book series: Oncologie pratique ((ONCOLPRAT))

  • 236 Accesses

Abstrait

La première question est de pouvoir définir la population « âgée ». Si les Américains considèrent trois tranches, 65–74 ans (« young old »), 75–84 ans (« older old »), 85 ans et plus (« oldest old »), la tendance actuelle est plutôt de considérer comme âgée la population de plus de 70 voire 75 ans. La prise en charge des tumeurs urologiques des sujets âgés pose des problèmes pratiques courants de choix de stratégie thérapeutique et parfois un dilemme entre décision de traitement curatif ou palliatif. Or, il est important que ces patients ne soient pas victimes d’une discrimination concernant le traitement car le pronostic apparaît en règle indépendant de l’âge (à l’exception de tumeurs prostatiques rapidement é volutives de score de Gleason élevé rencontrées souvent chez des sujets plus jeunes). Pourtant on constate que cette population de patients reçoit moins souvent un traitement curatif sans que la décision soit fondée sur des données validées.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Alberts DS, Dahlerg S, Green SJ et al. (1993) Analysis of age as an independant prognostic factor for survival in a phase III study of cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in stages III (suboptimal) and IV ovarian cancer. A Southwest Oncology Group Study. Cancer 71: 618–27

    Article  PubMed  CAS  Google Scholar 

  2. Albertsen PC, Fryback, Storer BE et al. (1996) The impact of co-morbidity on life expectancy among men with localized prostate cancer. J Urol 156: 127–32

    Article  PubMed  CAS  Google Scholar 

  3. Arias F, Duenas M, Martinez E et al. (1997) radical chemotherapy for elderly patients with bladder carcinoma invading muscle. Cancer 80: 115–20

    Article  PubMed  CAS  Google Scholar 

  4. Balducci L, Extermann M (1997) Cancer chemotherapy in the older patient. What the medical oncologist needs to know. Cancer 80: 1317–22

    Article  PubMed  CAS  Google Scholar 

  5. Bamias A, Aravantinos G, Deliveliotis C et al. Hellenic Cooperative Oncology Group (2004). docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. J Clin Oncol. 22: 220–8.

    Article  PubMed  CAS  Google Scholar 

  6. Baumann M (1998). Is curative radiation therapy in the elderly patients limited by increased normal tissue toxicity? Radiother Oncol 46: 225–7

    Article  PubMed  CAS  Google Scholar 

  7. Becouarn Y, Bui BN, Brunet R et al. (1992) Cancer chemotherapy in the elderly: a series of 51 patients aged > 70 years. Cancer Chemotherapy pharmacol 29: 159–63

    Article  Google Scholar 

  8. Beuzeboc P (2000) Chimiothérapie adjuvante ou néoadjuvante dans les cancers invasifs de la vessie et des voies excrétrices supérieures. Oncologie 2;6/7: 348–56

    Google Scholar 

  9. Birch R, Kalman L, Holt L et al. (2004). Randomized phase II b trial comparing two schedules of docétaxel plus estramustine for metastatic hormone-refractory prostate cancer. Proc ASCO Abstr 4622

    Google Scholar 

  10. Bolla M, Gonzalez D, Warde P et al. (1997). Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337: 295–300

    Article  PubMed  CAS  Google Scholar 

  11. Chauvet B, Felix-Faure C, Davin JL et al. (1998) Résultats à long terme du traitement des cancers de la vessie inopérables par cisplatine et irradiation concomitante: facteurs pronostiques du contrôle local et de la survie. Cancer/Radiother 2(suppl 1): 85s–91s

    Google Scholar 

  12. Coppin CML, Gospodarowicz MK, James K et al. (1996) Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. J Clin Oncol 14: 2901–7

    PubMed  CAS  Google Scholar 

  13. Culine S (2000). Chimiothérapie des tumeurs urothéliales métastatiques de la vessie et des voies excrétrices supérieures. Oncologie 2;6/7: 357–65

    Google Scholar 

  14. Damhuis RAM, Blom J (1995) The influence of age on treatment choice and survival in 735 patients with renal carcinoma. Br J Urology 75: 143–47

    Article  CAS  Google Scholar 

  15. Damhuis RAM, Kirkels WJ and the EUROCARE working group (1998) Improvement in survival of patients with cancer of the kidney in Europe. Eur J Cancer 34;14: 2232–5

    Article  CAS  Google Scholar 

  16. Denis LJ, Murphy GP, Schröder FH (1995) Report of the consensus workshop on the screening and global strategy for prostate cancer. Cancer 75: 1187–207

    Article  PubMed  CAS  Google Scholar 

  17. Eapen L, Stewart D, Grimard L et al. (1998) Treatment of cancer of the bladder in elderly patients with an intra-arterial chemotherapy and radiotherapy combination: 10-year experience. Cancer Radiother 2(suppl 1):73S–76S

    PubMed  Google Scholar 

  18. Edmonson JH, SU J, Krook JE (1993). Treatment of ovarian cancer in elderly women. Mayo Clinic-North central Cancer Treatment Group Studies. Cancer 71;2: 615–7

    Article  PubMed  CAS  Google Scholar 

  19. Eisenberger MA, Blumenstein BA, Crawford D et al. (1998) Bilateral orchidectomy with or without flutamide for metastatic prostate cancer. N Engl J Cancer 339: 1036–42

    Article  CAS  Google Scholar 

  20. Flanigan RC, Ynover PM (2001). The role of resection for patients with renal carcinoma. Review. Curr Oncol Rep. 3(5): 424–32

    Article  PubMed  CAS  Google Scholar 

  21. Font A, Esteban E, Carles J et al. (2004) Gemcitabine and oxaliplatin (GEMOX) combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer. Proc ASCO, Abstr 4544

    Google Scholar 

  22. Gelman RS, Taylor SG (1984) Cyclophosphamide, methotrexate, and 5-fluorouracil in women more than 65 years old with advanced breast cancer: the elimination of age trends in toxicity by using doses based on creatinine clearance. J Clin Oncol 2: 1406–14

    Google Scholar 

  23. Holmberg L, Bill-Axelson A, Helgesen F et al. (2002) for the Scandinavian Prostatic Cancer Group Study number 4. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 347,11: 781–9

    Article  PubMed  Google Scholar 

  24. Housset M, Maulard C, Chretien Y et al. (1993) Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. J Clin Oncol 11: 2150–7

    PubMed  CAS  Google Scholar 

  25. Housset M, Dufour B, Maulard-Durdux C et al. (1997) Concomitant fluorouracil-cisplatin and bifractionated split course radiation therapy for invasive bladder cancer. Proc ASCO 319a: abstr 1139

    Google Scholar 

  26. Hrushesky WJ, Shimp W, Kennedy BJ (1984). Lack of age-dependant cisplatin toxicity. Am J Med 76: 304–9

    Article  Google Scholar 

  27. International collaboration of trialists on behalf of the Medical Researh Council Advanced Bladder Cancer Working Party, EORTC Genito-Urinary Group (1999) Neoadjuvant cisplatin,methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. Lancet 354: 533–40

    Article  Google Scholar 

  28. Joly F, Tchen N, Chevreau C et al. (2004) Clinical benefit of second line weekly paclitaxel in advanced urothelial carcinoma: a GETUG phase II study. Proc ASCO, Abstr 4619

    Google Scholar 

  29. Kachnic LA, Kaufman DS, Heney NM et al. (1997) Bladder preservation by combined modality therapy for invasive bladder cancer. J Clin Oncol 15: 1022–9

    PubMed  CAS  Google Scholar 

  30. Kantoff PW, Halabi S, Conaway M et al. (1999) Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 17: 2506–13

    PubMed  CAS  Google Scholar 

  31. Leibovitch I, Avigad I, Ben-Chaim J et al. (1993) Is it justified to avoid radical cystoprostatectomy in elderly patients with invasive transitional cell carcinoma of the bladder? Cancer 71: 3098–101

    Article  PubMed  CAS  Google Scholar 

  32. Lichtman SM, Buchholt ZM, Marino J et al. (1992) Aging 21:202–4

    CAS  Google Scholar 

  33. Loehrer PJ, Einhorn LH, Elson PJ et al. (1992) A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma:a cooperative group study. J Clin Oncol 10: 1066–73

    PubMed  Google Scholar 

  34. Marshall FF, Stewart AK, Menck HR (1997). The national Cancer Data Base: report on kidney cancers. The American College of surgeons Commission on Cancer and the American Cancer Society. Cancer 80: 2167–74

    Article  PubMed  CAS  Google Scholar 

  35. McLaren DB, Morrey D, Mason MD (1997) Hypofractionnated radiotherapy for muscleinvasive bladder cancer in the elderly. Radiother Oncol 43(2): 171–4

    Article  PubMed  CAS  Google Scholar 

  36. Miller BA, Hayes RB, Potosky AL et al.. In: Miller BA et al., editors. SEER Cancer Statistics Review: 1973–1990. Bethesda (MD): National Cancer Institute; NIH Pub No 93-2789

    Google Scholar 

  37. Monfardi S, Ferruci L, Fratino L et al. (1996) Validation of a multidimentional evaluation scale for use in elderly cancer patients. Cancer 77: 395–401

    Article  Google Scholar 

  38. Mottet-Auselo N, Bons-Rosset F, Costa P et al. (1993) Carboplatin and urothelial tumors. Oncology 50: 28–36

    Article  PubMed  Google Scholar 

  39. Motzer RJ, Rini BI, Michaelson MD et al. (2004) SU 11248 a novel tyrosine kinase inihibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: results of a phase 2 trial. Proc ASCO Abstr 4500

    Google Scholar 

  40. Oudard S, Banu E, Beuzeboc P et al. for the ARTIC group (2005) Superior activity of docetaxel, estramustine and rednisone regimens versus mitoxantrone and prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol. 23,15: 1–9

    Article  CAS  Google Scholar 

  41. Petrioli R, Frediani B, Manganelli A et al. (1996) Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study. Cancer 77: 344–51

    Article  PubMed  CAS  Google Scholar 

  42. Petrylak DP, Tangen CM, Hussain MH et al. (2004) Docétaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 351(15): 1513–20

    Article  PubMed  CAS  Google Scholar 

  43. Phillips HA, Howard GC (1998) The treatment of bladder cancer in the elderly. Radiother Oncol 46(3): 334–5

    Article  PubMed  CAS  Google Scholar 

  44. Pignon T, Horiot JC, Bolla M et al. (1997) Age is not a limiting factor for radical radiotherapy in pelvic malignancies. Radiother Oncol 42: 107–20

    Article  PubMed  CAS  Google Scholar 

  45. Ragde H, Korb LJ, Elgamal AA et al. (2000) Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up. Cancer 89: 135–41

    Article  PubMed  CAS  Google Scholar 

  46. Ratain MJ, Flaherty KT, Stadler WM et al. (2004) Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial. Proc ASCO Abstr 4501

    Google Scholar 

  47. Robert J, Hoerni B (1983) Age dependance of the early-phase pharmacokinetics of doxorubicin. Cancer Res 43: 4467–9

    PubMed  CAS  Google Scholar 

  48. Sataranio WA Ragland KE Van den Eeden 1998 Cause of death in men diagsed with prostate carcima. Cancer 83 1180–8

    Article  Google Scholar 

  49. Scalliet P. Radiotherapy in the Elderly (1991) Eur J Cancer 27: 3–5

    Google Scholar 

  50. Sella A, Logothetis J, Dexfus FH et al. (1991) Cisplatin combination chemotherapy for elderly patients with urothelial tumours. Br J Urol 67: 603–7

    PubMed  CAS  Google Scholar 

  51. Shepherd FA, Abratt RP, Anderson H et al. (1997) Gemcitabine in the treatment of elderly patients with advanced non-small cell lung cancer. Sem Oncol 24(suppl 7): 50–7

    CAS  Google Scholar 

  52. Shipley WU, Winter KA, Kaufman WR et al. (1998) Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol. 16: 3576–83

    PubMed  CAS  Google Scholar 

  53. Soulié M, Sraub M, Gamé X et al. (2002) A multicentric study of the morbidity of radical cystectomy in select elderly patients with bladder cancer. J Urol; 167: 1325–8

    Article  PubMed  Google Scholar 

  54. Sylvester JE, Blasko JC, Grimm PD et al. (2004) Fifteen year follow up of the first cohort of localized prostate cancer patients treated with brachytherapy. Proc ASCO Abstr 4567

    Google Scholar 

  55. Tannock I, Osoba D, Stockler MR et al. (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a canadian randomized trial with palliative end points. J Clin Oncol 14: 1756–64

    PubMed  CAS  Google Scholar 

  56. Tannock IF, de Wit R, Berry WR et al. TAX 327 Investigators (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl; 351(15): 1502–12

    Article  CAS  Google Scholar 

  57. The Elderly Lung Cancer Vinorelbine Italian Study Group (1999) Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 91: 66–72

    Article  Google Scholar 

  58. Thyss A, Saudes L, Otto J et al. (1994) Renal tolerance of cisplatin in patients more than 80 years old. J Clin Oncol 12: 2121–5

    PubMed  CAS  Google Scholar 

  59. Vestal RE (1997). Aging and pharmacology. Cancer 80: 1302–10

    Article  PubMed  CAS  Google Scholar 

  60. Von der Maase H, Hansen SW, Roberts JT et al. (2000) Gemcitabine and cisplatine versus methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy in advanced or metastatic transitional cell carcinoma of the urothelium: a large randomized multicenter, multinational phase III study. J Clin Oncol; 18(17): 3068–77

    PubMed  Google Scholar 

  61. Vrouvas J, Dodwell D, Ash D et al. (1995) Split course radiotherapy for bladder cancer in elderly unfit patients. Clin Oncol 7(3):193–195

    Article  CAS  Google Scholar 

  62. Winquist E, Kirchner TS, Segal R, Chin J and Lukka H on the behalf oh the Genitourinary Cancer Disease Site Group of Cancer Care Ontario Program in evidence-based care practice guidelines initiative (2004) Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol. 171/561–9

    Article  PubMed  CAS  Google Scholar 

  63. Yamamoto N, Tamura T, Maerla M et al. (1995) The influence of aging on cisplatin pharmacokinetics in lung cancer patients with normal organ function. Cancer Chemother Pharmacol 36: 102–6

    Article  PubMed  CAS  Google Scholar 

  64. Yancik R (1997) Cancer burden in the aged. Cancer 80:1273–83

    Article  PubMed  CAS  Google Scholar 

  65. Zachariah B, Balducci L, Venkattaramanabalaji GV et al. (1997) Radiotherapy for cancer patients age 80 and older; a study of effectiveness and side effects. Int J Radiat Oncol Biol Phys 39: 1125–9

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service d’oncologie médicale, 26, rue d’Ulm, 75005, Paris

    Philippe Beuzeboc

Authors
  1. Philippe Beuzeboc
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Service d’oncologie médicale, CHU Avicenne, 125, rue de Stalingrad, 93009, Bobigny Cedex

    Jean-François Morère

  2. Centre de gériatrie, Hôpital Xavier-Arnozan, Avenue du Haut-Levêque, 33604, Pessac

    Muriel Rainfray

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer-Verlag France

About this chapter

Cite this chapter

Beuzeboc, P. (2007). Tumeurs urologiques du sujet âgé. In: Morère, JF., Rainfray, M. (eds) Cancer du sujet âgé. Oncologie pratique. Springer, Paris. https://doi.org/10.1007/978-2-287-48618-0_13

Download citation

  • DOI: https://doi.org/10.1007/978-2-287-48618-0_13

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-25209-9

  • Online ISBN: 978-2-287-48618-0

Publish with us

Policies and ethics

Search

Navigation